EPILEPSY

Antisense oligonucleotide hope for childhood epilepsies

Treatment with an antisense oligonucleotide increases survival in mouse models of two epileptic encephalopathies, according to a recent study. The antisense oligonucleotide was against the SCN8A transcript, which encodes the sodium channel NaV1.6. Mutations in this channel lead to a gain of function that causes SCN8A encephalopathy, characterized by severe, frequent seizures. The condition is similar to Dravet syndrome, which is caused by mutations in SCN1A. Guy Lenk and colleagues used the antisense oligonucleotide to treat mice with Scn8a mutations or Dravet syndrome. Mean survival increased from 15 days to 65 days in the model of SCN8A encephalopathy and from 3 weeks to >5 months in the model of Dravet syndrome. The results suggest that this approach is promising as a therapy for intractable childhood epilepsies.

References

Original article

  1. Lenk, G. M. et al. Scn8a antisense oligonucleotide is protective in mouse models of SNC8A encephalopathy and Dravet syndrome. Ann. Neurol. https://doi.org/10.1002/ana.25676 (2020)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ian Fyfe.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fyfe, I. Antisense oligonucleotide hope for childhood epilepsies. Nat Rev Neurol 16, 128 (2020). https://doi.org/10.1038/s41582-020-0319-5

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing